Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue—
Net Income-$6.88M-$6.88MN/M vs Q2 2024 EPS Diluted-$0.22-$0.22N/M vs Q2 2024 Operating Income-$7,503,000N/M Operating Cash Flowderived-$5,392,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 8, 2025 · 39 d after period end